课题基金 / 基金详情

Antidote for inhaled CO poisoning based on mutationally engineered neuroglobin

Antidote for inhaled CO poisoning based on mutationally engineered neuroglobin
基于突变工程神经球蛋白的吸入一氧化碳中毒解毒剂
批准号:
8801711
负责人:
Mark T Gladwin
金额:
$61.38万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-12-01 至 2018-11-30
关键词:
AcuteAddressAffectAffinityAlanineAnimal ModelAntidotesApoptosisBindingBiologicalBlood CirculationBlood gasBrainBrain EdemaBrain InjuriesBreathingCarbon MonoxideCarbon Monoxide PoisoningCardiacCarrying CapacitiesCause of DeathCessation of lifeCitiesClinical DataCognitiveCytochromesDataDevelopmentDiagnosisDistalDivingElectron TransportEmergency department visitEngineeringEnzymesErythrocytesExcisionExhibitsExposure toFamily suidaeFire - disastersFunctional disorderGas PoisoningGasesGenus HippocampusGlutamineHalf-LifeHeartHemeHeme IronHemeproteinsHemoglobinHemoglobin concentration resultHistidineHome environmentHumanHuman EngineeringHyperbaric OxygenHyperbaric OxygenationHyperbaric TherapyHypoxiaImageImpaired cognitionIn VitroIncubatedInfusion proceduresInjuryIntensive CareKidneyLaboratoriesLasersLeucineLigandsLungMagnetic Resonance ImagingMammalsMeasuresMechanical ventilationMetabolic Clearance RateMetabolic acidosisMethodologyMitochondriaModelingMusMutagenesisMutationMyoglobinNecrosisNeuraxisNeurocognitive DeficitNeurologicNormal RangeOrganOxidasesOxygenOxygen Therapy CareParamedical PersonnelPatientsPersonsPhysiologyPlantsPoisoningPreparationReperfusion InjuryRespirationRiskSalineSeriesSolubilitySolutionsStructureSulfhydryl CompoundsSurfaceSystemTNFRSF5 geneTestingTherapeuticTimeTissuesToxic effectTransportationUnited StatesUrineWaterbasecapsulecombinatorialcomplex IVcytochrome c oxidasedisabilityexhaustextracellularflash photolysisimprovedin vivomutantneuroglobinoxidationplanetary Atmospherepre-clinicalpressurepublic health relevanceresearch studyretinal rodstranslational studytreatment center

项目摘要

项目成果

Mark T Gladwin的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Blood gas poisoning with carbon monoxide (CO) remains a major cause of death and disability, affecting 50,000 persons a year in the U.S. alone. Patients with greater than 30% carboxyhemoglobinemia may develop brain injury, long-term neurocognitive deficits, and/or death. In the present proposal we introduce the first antidotal therapy for carbon monoxide poisoning, based on the finding of a surprising and near-irreversible CO-binding affinity of mutationally engineered human neuroglobin. Neuroglobin, like cytoglobin and many plant Hbs, is a six-coordinate hemoprotein, with the heme iron coordinated by a proximal and distal histidine residues. In an effort to understand the function of this bis-histidyl structure, we performed mutagenesis of the proximal histidine 64 molecule (e.g. H64Q) which opens the heme pocket, forming a five-coordinate molecule, more similar to the heme pocket of Hb or myoglobin. Unexpectedly, this molecule exhibits a remarkably high affinity for gaseous ligands, with a P50 value for oxygen (PaO2 value at which 50% of the heme binds oxygen) of 0.01 mm Hg (normal value is 26 mm Hg). This finding informs our primary hypothesis, that H64 mutant neuroglobin will bind CO with high affinity, producing a five-coordinate "trap" for CO. In our preliminary experiments we find that mutationally engineered H64Q neurglobin binds CO with an affinity more than 300 times that of hemoglobin and can remove CO from intact red cells in vitro and in vivo in CO exposed mice in less than 2 minutes. We propose to refine this molecule in a series of in vitro, pre-clinical physiology, and translational studies as a human biological antidote for CO poisoning and test its ability to clear CO from red blood cells, critical organs (lung, brain, and heart), and cytochrome C oxidase of the mitochondrial electron transport chain. From a translational perspective, will test the ability of this antidote to improve long-term organ function and survival after severe CO poisoning.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Sickle Cell Disease and Cardiovascular Risk- Red Cell Exchange SCD-CARRE
  • 批准号:
    10653703
  • 项目类别:
  • 资助金额:
    $335.0万
  • 财政年份:
    2022
  • 负责人:
    Mark T Gladwin
  • 依托单位:
1/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE Trial)
1/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE Trial)
1/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE Trial)
海外基金